Trial Profile

An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Azathioprine; Prednisone
Indications Crohn's disease
Focus Therapeutic Use
Acronyms CALM
Sponsors AbbVie

Most Recent Events

08 Jul 2019 Results evaluating the use of Adalimumab in a Tight Control (TC) approach with both biomarker-based and clinical symptom-directed strategy is cost-effective compared with Clinical Management (CM), are published in the Gut.
16 Oct 2018 According to an AbbVie media release, data will be presented at United European Gastroenterology (UEG) Week 2018.
01 Nov 2017 Results presented at the 25th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com